Mounjaro rules: what actually applies before, during and after treatment

Step 1: the eligibility rules that apply before a prescription is written

Before any Mounjaro prescription is issued, a prescriber must satisfy themselves that the medicine is clinically appropriate for you. The licensed criteria, set out in the Mounjaro Summary of Product Characteristics and reflected in NICE's appraisal of tirzepatide (TA1026), centre on BMI and the presence of weight-related conditions. The licensed threshold for weight management is a BMI of 30 or above, or 27 or above if you have at least one qualifying condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. NICE's recommendation for NHS use applies a higher bar of BMI 35 or above plus at least one comorbidity, though private prescribing follows the licensed SmPC criteria.

Ethnic-background adjustments matter here. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance reduces each threshold by 2.5 kg/m². That adjustment is part of the rules, not an informal concession. A prescriber also reviews your medical history for conditions that make Mounjaro unsuitable, a history of medullary thyroid carcinoma, certain gastrointestinal conditions or a previous episode of pancreatitis all require careful discussion before treatment begins. BMI alone never settles the question. The prescriber looks at the whole picture.

At our clinical team, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted. That person applies these rules personally to your case, rather than running your answers through a scoring system. If you have questions about whether you are likely to qualify, our FAQs page covers the most common eligibility queries.

Step 2: the titration rules that govern how your dose increases

One of the mounjaro rules UK readers most often search for is the dose schedule. Mounjaro comes in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. The first pen is always 2.5mg. Its job is to give your body time to adjust, gastrointestinal side effects are most likely in the early weeks, and the starter dose is deliberately low to reduce their severity. Many people find that nausea settles considerably between weeks two and four at this level.

From there, your prescriber decides when it is appropriate to move up, typically at four-week intervals, based on how you are tolerating the current dose. You cannot self-escalate. That rule protects you, as moving up too quickly significantly increases the risk of side effects without delivering meaningfully better outcomes at that point. If tolerability is a problem at any stage, staying longer at the current dose or stepping back is also a clinical option. The titration schedule is a conversation, not a conveyor belt.

For anyone transferring from another provider or requesting a dose increase, evidence of current treatment is required before the higher dose is authorised. That check is part of the Mounjaro treatment process at every regulated clinic, not just ours. Our clinical lead reviews all transfer and dose-increase requests personally. The NHS tirzepatide medicines page also sets out the practical rules around administration, injection sites and storage in plain language.

Step 3: the ongoing monitoring rules that apply for as long as you are on treatment

A Mounjaro prescription is not a one-off transaction. The rules require clinical review before every repeat supply. That means your prescriber assesses progress, checks for new health information, reviews any side effects you have reported and confirms the dose remains appropriate. A repeat issued without any of this would not meet GPhC or MHRA standards for prescribing a Prescription-Only Medicine.

In practical terms, this is one reason a legitimate supply chain involves a structured aftercare process rather than a simple refill button. If you order by midday Monday to Friday at our consultation hub, a prescriber reviews your case the same day, and that review genuinely happens before dispatch, not as a formality afterwards.

There are also specific rules around particular situations. Women using oral contraceptive pills should add a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying in a way that can reduce pill absorption. If you are taking HRT, discussing whether a transdermal formulation would be preferable is worth raising with your prescriber. Before any surgical procedure, tell both your surgeon and anaesthetist that you are taking Mounjaro. These are not optional recommendations, they are part of the clinical framework around the medicine. More detail on the cost of private treatment sits on our Mounjaro price comparison page, if that question is running alongside the clinical ones.

Mounjaro is also a Black Triangle medicine, meaning the MHRA requires additional monitoring. If you notice a side effect that concerns you, report it via the Yellow Card scheme. Your report contributes to the safety database that makes the medicine better understood over time.

Pregnancy and breastfeeding are clear contraindications, Mounjaro is not recommended if you are pregnant, trying to conceive or breastfeeding, and it is not licensed for under-18s. These rules are absolute, not a matter of prescriber discretion. Patients based outside the UK, for example those looking at accessing Mounjaro in the Czech Republic, should be aware that eligibility and prescribing frameworks may differ from those described here.